Wang Z, Fan J, Zhou S, Sun Y, et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial. Lancet 2025 Oct 19:S0140-6736(25)01720-9. doi: 10.1016/S0140-6736(25)01720.
PMID: 41125112